May 2026 Research Update

This month added a clear example of how gene testing can pin down a Sanfilippo diagnosis in settings where enzyme or other lab tests are hard to access. In two Pakistani families with mucopolysaccharidosis signs, sequencing found a disease-causing change in the SGSH gene consistent with MPS IIIA in one family, while the second family had a different MPS type (MPS IVA) caused by a different gene. This matters because families with similar-looking symptoms may have different subtypes, and genetics can be the deciding evidence. [1]

In the family affected by MPS IIIA, all affected siblings carried the same homozygous SGSH change (p.Cys183Tyr), and the study reported that it tracked with the condition within the family. Computer-based protein modeling suggested this change could destabilize the SGSH protein, offering a possible biological explanation for how the variant could disrupt enzyme function. The report also noted that they did not have biochemical confirmation, so the genetic result carried most of the diagnostic weight in this setting. [1]

For patients and caregivers, this mainly adds understanding about diagnosis rather than changing day-to-day care. It shows that genetic testing can sometimes provide a specific answer about the subtype (such as MPS IIIA) even when enzyme testing is not available, which can support family planning discussions and help families connect with subtype-specific research. What remains uncertain here is how strongly this exact SGSH change affects enzyme activity in real-life biology, because the study relied on computer predictions and did not include enzyme testing. [1]

This month provided a close look at how widespread Sanfilippo syndrome type IIIA can be in later-stage disease. A single autopsy report described storage material and related cell changes across the brain and several major organs, not just the nervous system. For families, the key message is that the condition can involve multiple body systems as it progresses, even though brain symptoms are often the most visible. [2]

In this case, the report described marked brain changes alongside clear findings in the heart, liver and spleen, kidneys, and the gastrointestinal tract, with many cells showing vacuoles consistent with storage. The study also described activated immune-type cells (CD68-positive macrophages) in both brain and body tissues, which helps explain why inflammation-like tissue changes may appear alongside storage. Because this is one person, it cannot show how common each organ finding is, but it makes the multisystem nature of the disease easier to picture. [2]

For patients and caregivers, this is most useful for understanding the big picture of the illness rather than predicting exactly what will happen for any one person. It supports the idea that symptoms and complications can come from more than the brain alone, which may matter for discussions about supportive care needs over time. What remains uncertain is how typical the exact pattern is, since the report was limited to a single case and did not include genetic confirmation in that individual. [2]

This month included early-stage research that tries to sort which gene changes are most likely to disrupt the enzyme involved in Sanfilippo type B (MPS IIIB). Using computer analyses across many reported NAGLU missense variants, the study highlighted one variant (I154R) as especially damaging in their models. The main value for patients right now is building a clearer map of which variants might be high-impact, which can guide what to test next in the lab. [3]

In the modeling, the I154R change was predicted to destabilize the NAGLU protein and weaken how well it binds a small sugar-like molecule used to represent part of its normal activity. The study also reported differences in simulated protein behavior between the normal and mutant forms, consistent with reduced stability and weaker binding. These are still predictions, and the authors noted that real enzyme testing and other experiments would be needed to confirm whether the same effects occur in living cells and under lysosomal conditions. [3]

For families, this is research that may matter later rather than something used in routine care today. It helps clarify why two people with different NAGLU variants might not have the same enzyme function, by showing how a specific change could alter the protein's shape and binding in a model. What remains uncertain is how well these computer results match real biology, because the work did not measure enzyme activity in patient samples. [3]